🔍 Description:

B7-33 is a synthetic peptide derived from the naturally occurring H2-relaxin protein. This single-chain peptide has been developed to retain the potent anti-fibrotic properties of relaxin while minimizing some of its potential side effects. Unlike the full H2-relaxin protein, which can activate the cAMP pathway and potentially promote tumor growth, B7-33 primarily activates the pERK pathway. This makes B7-33 a promising therapeutic agent for reducing fibrosis in various acute and chronic conditions, including heart failure, lung inflammation, and other fibrotic disorders.

B7-33 binds to the RXFP1 receptor with high affinity, promoting matrix metalloproteinase 2 (MMP2) expression, which degrades extracellular collagen. This action significantly reduces excessive scar formation following tissue injury. Additionally, B7-33’s unique mechanism does not increase cAMP production, a feature that potentially reduces its tumor-promoting effects.

💪 Health Benefits:

– Anti-Fibrotic Effects: B7-33 reduces fibrosis by up to 50% in animal studies, showing promise in treating heart failure, lung fibrosis, and other fibrotic conditions.

– Cardiovascular Protection: B7-33 has been shown to reduce excessive scar formation following cardiac injury, thereby improving heart function and prolonging survival after myocardial infarction.

– Vascular Health: B7-33 has potential applications in treating vascular disorders and preeclampsia by protecting against endothelial dysfunction and promoting blood vessel relaxation.

– Potential Cancer Safety: Unlike full-sequence relaxin, B7-33 does not promote tumor growth even at higher doses, making it a safer option in anti-fibrotic therapy.

– Reduction of Foreign Body Response: B7-33 can be used as a coating on medical implants to reduce fibrotic capsule formation, which is critical for the long-term success of implants like cardiovascular stents.

💉 Dosing/Administration:

– Typical Dosing: The exact dosage for B7-33 is still under research, but in animal models, it has been administered in amounts sufficient to achieve significant anti-fibrotic effects without promoting tumor growth.   Edit:   It is reported below that dosing can be 100mcg to 200 mcg per administration.   With a reported half life of of an hour or so, multiple doses may be administered per day.

– Administration Method: B7-33 is typically administered via injection. 

– Cycling: B7-33’s administration would likely follow protocols similar to other peptides used for chronic conditions, with ongoing or repeated dosing based on the therapeutic need and patient response.

⚠️ Side Effects and Safety:

– Minimal Side Effects: B7-33 is designed to avoid the cAMP pathway activation associated with tumor growth, making it a safer option compared to H2-relaxin.

– Fibrosis Reduction without Cancer Risk: B7-33 does not promote cancer progression in preclinical models, even when administered at doses higher than those needed for anti-fibrotic effects.

– Storage and Stability: As with other peptides, B7-33 should be stored in a cool, dry place, and proper handling protocols should be followed to maintain its stability and efficacy.

💡 Additional Research Insights:

– Ease of Production: B7-33 is easier to produce than full H2-relaxin due to its less complex structure, making it a cost-effective option for therapeutic development.

– Potential in Preeclampsia: Research suggests that B7-33 may improve blood supply between mother and fetus by promoting VEGF production in cytotrophoblasts, making it a potential treatment for preeclampsia.

– Anti-Fibrotic Material Development: B7-33 is being explored as a coating for medical implants to reduce the foreign body response, which could revolutionize the design and longevity of implantable medical devices.